LENZ Therapeutics Secures Exclusive Australian and New Zealand VIZZ License with Upfront Payment and Profit Share
LENZ•LENZ Therapeutics granted Arrotex exclusive license and commercialization rights for VIZZ in Australia and New Zealand, receiving an upfront payment plus a significant share of gross margin profits. VIZZ 1.44% aceclidine ophthalmic solution, the first FDA-approved presbyopia eye drop, has been commercially available in the US since October 2025.
1. Agreement Details
LENZ Therapeutics granted Arrotex Pharmaceuticals exclusive rights to register and commercialize VIZZ in Australia and New Zealand. Under the deal, LENZ receives an upfront licensing payment plus a significant share of gross margin profits from all product sales in the region.
2. Partnership Significance
Arrotex, Australia’s largest diversified pharmaceutical company, brings extensive pharmacy networks and commercial expertise to accelerate VIZZ adoption. This marks LENZ’s fifth ex-US partnership, furthering its global expansion strategy for presbyopia therapy.
3. Product Overview
VIZZ (aceclidine ophthalmic solution) 1.44% is the first FDA-approved aceclidine-based eye drop for presbyopia, delivering up to 10 hours of near vision improvement with a once-daily dose. It has been commercially available in the United States since October 2025.
4. Market Expansion Strategy
Presbyopia affects nearly all adults over 45, representing a potential market of over 1.8 billion people globally. This agreement positions LENZ to tap into the Australia and New Zealand markets, leveraging local infrastructure to drive adoption and revenue growth.
